Category: bone marrow transplant

  • Omeros seeks urgent FDA meeting after it rejects key drug

    Shares in Omeros plummeted yesterday after the FDA rejected approval of its narsoplimab drug for a rare and life-threatening complication of haematopoietic stem cell transplants (HSCT), saying it was struggling to gauge the treatment effect of the drug. The biotech is seeking a so-called ‘Type A’ meeting with the FDA to see how the application […]

  • Sanofi scoops up Kadmon and its newly approved drug in a $1.9B deal

    The cash deal brings to Sanofi the Kadmon Holdings drug Rezurock, which the FDA approved in July as a treatment for chronic graft versus host disease. The French pharmaceutical giant will add Rezurock to a lineup of older products marketed globally for transplant procedures.